Zimmer Biomet completes acquisition of Monogram Technologies for $4.04/sh plus CVRs up to $12.37

ZIMMER BIOMET HOLDINGS, INC.

Each Monogram common share converted to $4.04 cash and non-tradeable CVRs worth up to $12.37 upon milestone achievement.
Acquisition adds AI-driven semi- and fully autonomous robotics for TKA; FDA 510(k) clearance March 2025, commercialization expected early 2027.
Zimmer Biomet now offers broadest orthopedic robotics portfolio including ROSA platform; nearing 2,000 installations worldwide.
Monogram shares ceased trading on NASDAQ and will be delisted as of October 7, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.